Kymera Therapeutics, INC 10-Q quarterly reports

Kymera Therapeutics announced significant collaboration revenue from Gilead and Sanofi, alongside continued investment in R&D, leading to a net loss.

Kymera Therapeutics reported increased collaboration revenue and R&D expenses in Q1 2026, with cash reserves projected to last into 2029.

Kymera Therapeutics reports a significant increase in net losses for Q3 and the first nine months of 2025, alongside strategic program adjustments and a new collaboration.

Kymera Therapeutics reports increased losses and a strategic pipeline shift, securing significant funding to extend its cash runway into late 2028.

Kymera Therapeutics announces its Q1 2025 financial results, showcasing increased collaboration revenue and advancements in its clinical-stage targeted protein degradation programs.

Kymera Therapeutics reports a net loss of $62.5 million for the third quarter of 2024, while highlighting progress in its immunology pipeline and strategic decisions regarding oncology programs.

Kymera Therapeutics reports a net loss of $42.1 million for Q2 2024, while progressing its clinical programs and maintaining a strong cash position.

Kymera Therapeutics reported a net loss of $48.6 million for Q1 2024, while highlighting progress in clinical programs and a strong cash position.